)
)
Modus Therapeutics Investor Relations Material
Latest events
Q3 2024
Modus Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Modus Therapeutics Holding
Access all reports
Modus Therapeutics AB is a healthcare company engaged in the development of drugs for rare diseases. Its product Slevaoxin, is focused on alleviating the elevated levels of neutrophil extracellular traps, which could reduce the widespread damage to organs and tissues, and frequently leads to life-threatening organ failure and death. It also develops MPC-06-ID, a drug candidate to address infantile onset Idiopathic nephrotic syndrome in children below the age of 2.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
MODTX
Country
🇸🇪 Sweden